Seminars in Fetal & Neonatal Medicine
Volume 13, Issue 1 , Pages 44-52 , February 2008

Adjunctive therapies in chronic lung disease: Examining the evidence

  • Win Tin

      Affiliations

    • The James Cook University Hospital, Marton Road, Middlesbrough, TS4 3BW, UK
    • Corresponding Author InformationCorresponding author. Tel.: +44 (0)1642 854 834; fax: +44 (0)1642 854 874.
    • ,
  • Thomas E. Wiswell

      Affiliations

    • Centre for Neonatal Care, Florida Hospital Orlando, 2718 North Orange Avenue, Suite B, Orlando, FL 32804, USA

References 

  1. Weis CM, Cox CA, Fox WW. Oxygen therapy. In:  Spitzer AR editors. Intensive care of the fetus and newborn. St. Louis: Mosby; 1996;p. 538–545
  2. Tin W, Hey E. The medical use of oxygen: a century of research in animals and humans. Neo Reviews. 2003;4:e340–e349
  3. Campbell K. Intensive oxygen therapy as a possible cause of retrolental fibroplasia: a clinical approach. Med J Aust. 1951;ii:48–50
  4. Askie LM, Henderson-Smart DJ. Restricted versus liberal oxygen exposure for preventing morbidity and mortality in preterm or low birth weight infants. Cochrane Database Syst Rev. 2000;(2):CD001077
  5. Northway WH, Rosan RC, Porter DY. Pulmonary disease following respirator therapy of hyaline-membrane disease. Bronchopulmonary dysplasia. N Engl J Med. 1967;267:357–368
  6. Saugstad OD. Bronchopulmonary dysplasia – oxidative stress and oxidants. Semin Neonatol. 2003;8:39–49
  7. The STOP-ROP Multicenter Study Group. Supplemental therapeutic oxygen for prethreshold retinopathy of prematurity (STOP-ROP), a randomized, controlled trial. I: primary outcomes. Pediatrics. 2000;105:295–310
  8. Askie LM, Henderson-Smart DJ, Irwig L, Simpson JM. Oxygen-saturation targets and outcomes in extremely preterm infants. N Engl J Med. 2003;349:959–967
  9. Flynn JT, Bancalari E, Snyder ES, Goldberg RN, Feuer W, et al. A cohort study of transcutaneous oxygen tension and the incidence and severity of retinopathy of prematurity. N Engl J Med. 1992;326:1050–1054
  10. Tin W, Milligan DWA, Pennefather PM, Hey E. Pulse oximetry, severe retinopathy, and outcome at one year in babies of less than 28 weeks gestation. Arch Dis Child. 2001;84:F106–F110
  11. Chow L, Wright KW, Sola S. Can changes in clinical practice decrease the incidence of severe retinopathy in very low birth weight infants?. Pediatrics. 2003;111:339–345
  12. Anderson CG, Benitz WE, Madan A. Retinopathy of prematurity and pulse oximetry: a national survey of recent practices. J Perinatol. 2004;24:164–168
  13. Sun SC. Relation of target SpO2 levels and clinical outcome in ELBW infants on supplemental oxygen. Pediatr Res. 2002;51:A350
  14. Bradley S, Anderson K, Tin W, et al. Early oxygen exposure and outcome at 10 years in babies of less than 28 weeks gestation. Pediatr Res. 2004;55:A373
  15. Poets C, Arand J, Hummler H, et al. Retinopathy of prematurity: a comparison between two centers aiming for different pulse oximetry saturation levels. Biol Neonate. 2003;84:A267
  16. Vijayakumar E, Ward GJ, Bullock CE, Patterson ML. Pulse oximetry in infants <1500gm birth weight on supplemental oxygen: a national survey. J Perinatol. 1997;17:341–345
  17. Tin W, Wariyar U. Giving small babies oxygen: 50 years of uncertainty. Semin Neonatol. 2002;7:361–367
  18. Silverman WA. A cautionary tale about supplemental oxygen: the albatross of neonatal medicine. Pediatrics. 2004;113:394–396
  19. Millar D, Schmidt B. Controversies surrounding xanthine therapy. Semin Neonatol. 2004;9:239–244
  20. Weinberg BA, Bealer BK. The world of caffeine: the science and culture of the world's most popular drug. New York/London: Routledge, Taylor and Francis; 2002;
  21. Davi MJ, Sankaran K, Simons KJ, Simons FE, Seshia MM, et al. Physiologic changes induced by theophylline in the treatment of apnea in preterm infants. J Pediatr. 1978;92:91–95
  22. Von Poblotzki M, Rieger-Fackeldey E, Schulze A. Effects of theophylline on the pattern of spontaneous breathing in preterm infants less than 1000g of birth weight. Early Hum Dev. 2003;72:47–55
  23. Rigatto H, Desai U, Leahy F, Kalapesi Z, Cates D. The effect of 2% CO2, 100% O2, theophylline and 15% O2 on ‘inspiratory drive’ and ‘effective’ timing in preterm infants. Early Hum Dev. 1981;5:63–70
  24. Henderson-Smart DJ, Steer PA. Prophylactic methylxanthine for prevention of apnea in preterm infants. Cochrane Database Syst Rev. 1999;(2):CD000432
  25. Henderson-Smart DJ, Steer P. Doxapram versus methylxanthine for apnea in preterm infants. Cochrane Database Syst Rev. 2000;(4):CD000075
  26. Henderson-Smart DJ, Steer P. Methylxanthine treatment for apnea in preterm infants. Cochrane Database Syst Rev. 2001;(3):CD000140
  27. Henderson-Smart DJ, Davis PG. Prophylactic methylxanthines for extubation in preterm infants. Update of Cochrane Database Syst Rev 2000;(2):CD000139 Cochrane Database Syst Rev. 2003;(1):CD000139
  28. In:  Hey E editors. Neonatal formulary. 4th ed.. London: BMJ Books; 2003;
  29. Schmidt B, Roberts RS, Davis P, Doyle LW, Barrington KJ, et al. Caffeine therapy for apnoea of prematurity. N Engl J Med. 2006;354:2112–2121
  30. Schmidt B, Roberts RS, Davis P, et al. The International Caffeine for Apnea of Prematurity (CAP) trial: preliminary analysis of outcomes at a corrected age of 18–21 months. E-PAS. 2007;61:5130.1
  31. Halliday HL, Ehrenkranz RA, Doyle LW. Early (<96hours) postnatal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev. 2003;(1):CD001146
  32. Halliday HL, Ehrenkranz RA, Doyle LW. Moderately early (7–14 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev. 2003;(1):CD001144
  33. Halliday HL, Ehrenkranz RA, Doyle LW. Delayed (>3 weeks) postnatal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev. 2003;(1):CD001145
  34. Shah SS, Ohlsson A, Halliday HL, et al. Inhaled versus systemic corticosteroids for preventing chronic lung disease in ventilated very low birth weight preterm neonates. Cochrane Database Syst Rev. 2003;(1):CD002058
  35. Shah SS, Ohlsson A, Halliday HL, Shah VS. Inhaled versus systemic corticosteroids for the treatment of chronic lung disease in ventilated very low birth weight preterm infants. Cochrane Database Syst Rev. 2003;(1):CD002057
  36. American Academy of Pediatrics, Committee on Fetus and Newborn; Canadian Pediatric Society, Fetus and Newborn Committee. Postnatal corticosteroids to treat or prevent chronic lung disease in preterm infants. Pediatrics. 2002;109:330–338
  37. Doyle LW, Davis PG, Morley CJ, McPhee A, Carlin JB DART Study Investigators. Low-dose dexamethasone facilitates extubation among chronically ventilator-dependent infants: a multicenter, international, randomised, controlled trial. Pediatrics. 2006;117:75–83
  38. Doyle LW, Davis PG, Morley CJ, McPhee A, Carlin JB DART Study Investigators. Outcome at 2 years of age of infants from the DART study: a multicenter, international, randomised controlled trial of low-dose dexamethasone. Pediatrics. 2007;119:716–721
  39. Doyle LW, Halliday HL, Ehrenkranz RA, Davis PG, Sinclair JC. Impact of postnatal systemic corticosteroids on mortality and cerebral palsy in preterm infants: effect modification by risk for chronic lung disease. Pediatrics. 2005;115:655–661
  40. Brion LP, Soll RF. Diuretics for respiratory distress syndrome in preterm infants. Cochrane Database Syst Rev. 2001;(2):
  41. Brion LP, Primhak RA. Intravenous or enteral loop diuretics for preterm infants with (or developing) chronic lung disease. Cochrane Database Syst Rev. 2000;(4):CD001453
  42. Brion LP, Primhak RA, Yong W. Aerosolized diuretics for preterm infants with (or developing) chronic lung disease. Cochrane Database Syst Rev. 2006;(3):
  43. Brion LP, Primhak RA, Ambrosio-Perez I. Diuretics acting on the distal renal tubule for preterm infants with (or developing) chronic lung disease. Update of Cochrane Database Syst Rev 2000;(3):CD001817 Cochrane Database Syst Rev. 2002;(1):CD001817
  44. Kinsella JP, Abman SH. Clinical approach to inhaled nitric oxide therapy in the newborn with hypoxemia. J Pediatr. 2000;136:717–726
  45. Kang JL, Park W, Pack IS, Lee HS, Kim MJ, et al. Inhaled nitric oxide attenuates acute lung injury via inhibition of nuclear factor-kappa B and inflammation. J Appl Physiol. 2002;92:795–801
  46. Ballard PL, Gonzales LW, Godinez RI, Godinez MH, Savani RC, et al. Surfactant composition and function in a primate model of infant chronic lung disease: effect of inhaled nitric oxide. Pediatr Res. 2006;59:157–162
  47. McCurnin DC, Pierce RA, Chang LY, Gibson LL, Osborne-Lawrence S, et al. Inhaled NO improves early pulmonary function and modifies lung growth and elastin deposition in a baboon model of neonatal chronic lung disease. Am J Physiol Lung Cell Mol Physiol. 2005;288:L450–L459
  48. Roberts JD, Polaner DM, Lang P, Zapol WM. Inhaled nitric oxide in persistent pulmonary hypertension of the newborn. Lancet. 1992;340:818–819
  49. Kinsella JP, Neish SR, Shaffer E, Abman SH. Low-dose inhalational nitric oxide in persistent pulmonary hypertension of the newborn. Lancet. 1992;340:819–820
  50. Finer NN, Barrington KJ. Nitric oxide for respiratory failure in infants born at or near term. Cochrane Database Syst Rev 2006;(4):CD000399.
  51. Barrington KJ, Finer NN. Inhaled nitric oxide for respiratory failure in preterm infants. Cochrane Database Syst Rev. 2006;CD000509
  52. Banks BA, Seri I, Ischiropoulos H, Merrill J, Rychik J, et al. Changes in oxygenation with inhaled nitric oxide in severe bronchopulmonary dysplasia. Pediatrics. 1999;103:610–618
  53. Clark PL, Ekekezie II, Kaftan HA, et al. Safety and efficacy of nitric oxide in chronic lung disease. Arch Dis Child. 2002;86:F41–F45
  54. Kinsella JP, Walsh WF, Bose CL, Gerstmann DR, Labella JJ, et al. Inhaled nitric oxide in premature neonates with severe hypoxemic respiratory failure: a randomised controlled trial. Lancet. 1999;354:1061–1065
  55. Field D, Elbourne D, Truesdale A, Grieve R, Hardy P, et al. Neonatal ventilation with inhaled nitric oxide versus ventilatory support without inhaled nitric oxide for preterm infants with severe respiratory failure: the INNOVO multicentre randomised controlled trial (ISRCTN 17821339). Pediatrics. 2005;115:926–936
  56. Van Meurs KP, Wright LL, Ehrenkranz RA, Lemons JA, Ball MB, et al. Inhaled nitric oxide for premature infants with severe respiratory failure. N Engl J Med. 2005;353:13–22
  57. Schreiber MD, Gin-Mestan K, Marks JD, Huo L, Lee G, Srisuparp P. Inhaled nitric oxide in premature infants with the respiratory distress syndrome. N Engl J Med. 2003;349:2099–2107
  58. Kinsella JP, Cutter GR, Walsh WF, Gerstmann DR, Bose CL, et al. Early inhaled nitric oxide therapy in premature newborns with respiratory failure. N Engl J Med. 2006;355:354–364
  59. Ballard RA, Truog WE, Cnaan A, Martin RJ, Ballard PJ, et al. Inhaled nitric oxide in preterm infants undergoing mechanical ventilation. N Engl J Med. 2006;355:343–353
  60. Stark AR. Inhaled NO for preterm infants – getting to yes?. N Engl J Med. 2006;355:404–406
  61. Bancalari E. Changes in the pathogenesis and prevention of chronic lung disease of prematurity. Am J Perinatol. 2001;18:1–9
  62. Fowlie PW, Davis PG. Prophylactic intravenous indomethacin for preventing mortality and morbidity in preterm infants. Cochrane Database Syst Rev. 2002;(3):CD000174
  63. Schmidt B, Davis P, Moddemann D, Ohlsson A, Roberts RS, et al. Long-term effects of indomethacin prophylaxis in extremely-low-birth-weight infants. N Engl J Med. 2001;344:1966–1972
  64. Shah SS, Ohlsson A. Ibuprofen for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants. Cochrane Database Syst Rev. 2006;(1):CD004213
  65. Denjean A, Paris-Llado J, Zupan V, Debillon T, Kieffer F, et al. Inhaled salbutamol and beclomethasone for preventing broncho-pulmonary dysplasia: a randomised double-blind study. Eur J Pediatr. 1998;157:926–931
  66. Ng GY, da Silva O, Ohlsson A. Bronchodilators for the prevention and treatment of chronic lung disease in preterm infants. Cochrane Database Syst Rev. 2001;(3):CD003214
  67. Wilkie RA, Bryan MH. Effect of bronchodilators on airway resistance in ventilator-dependent neonates with chronic lung disease. J Pediatr. 1987;111:278–282
  68. Brundage KL, Mohsini KG, Froese AB, et al. Bronchodilator response to ipratropium bromide in infants with bronchopulmonary dysplasia. Am Rev Respir Dis. 1990;142:1137–1142
  69. Yuksel B, Greenough A. Ipratropium bromide for symptomatic preterm infants. Eur J Pediatr. 1991;150:854–857
  70. Watterburg KL, Murphy S. Failure of cromolyn sodium to reduce the incidence of bronchopulmonary dysplasia. Pediatrics. 1993;91:803–806
  71. Viscardi RM, Hasday JD, Gumpper KF, Taciak V, Campbell AB, et al. Cromolyn sodium prophylaxis inhibits pulmonary proinflammatory cytokines in infants at high risk for bronchopulmonary dysplasia. Am J Respir Crit Care Med. 1997;156:1523–1529
  72. Tyson JE, Wright LL, Oh W, Kennedy KA, Mele L, et al. Vitamin A supplementation for extremely-low-birth infants. National Institute of Child Health and Human Development Neonatal Research Network N Engl J Med. 1999;340:1962–1968
  73. Darlow BA, Graham PJ. Vitamin A supplementation for preventing morbidity and mortality in very low birth weight infants. Cochrane Database Syst Rev. 2002;(4):CD00501
  74. Wardle SP, Hughes A, Chen S, Shaw NJ. Randomised controlled trial of vitamin A supplementation in preterm infants to prevent chronic lung disease. Arch Dis Child. 2001;84:F9–F13
  75. Brion LP, Bell EF, Rughuveer TS. Vitamin E supplementation for prevention of morbidity and mortality in preterm infants. Cochrane Database Syst Rev. 2003;(4):CD003665
  76. Rosenfeld W, Evans H, Concepcion L, Jhaveri R, Shaeffer H, et al. Prevention of bronchopulmonary dysplasia by administration of bovine superoxide dismutase in preterm infants with respiratory distress syndrome. J Pediatr. 1984;105:781–785
  77. Davis JM, Rosenfeld WN, Richter SE, Parad MR, Gewolb IH, et al. Safety and pharmacokinetics of multiple doses of recombinant human CuZn superoxide dismutase administered intratracheally to premature neonates with respiratory distress syndrome. Pediatrics. 1997;100:24–30

PII: S1744-165X(07)00115-1

doi: 10.1016/j.siny.2007.09.008

Seminars in Fetal & Neonatal Medicine
Volume 13, Issue 1 , Pages 44-52 , February 2008

Article Tools

* Image Usage & Resolution